Internal Server Error

EsoBiotec - About the company

EsoBiotec is an acquired company based in Mont-Saint-Guibert (Belgium), founded in 2020. It operates as a Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production.. EsoBiotec has raised $2.15M in funding from investors like Thuja Capital, Sambrinvest and UCB Ventures. The company has 3627 active competitors, including 1201 funded and 819 that have exited. Its top competitors include companies like BeiGene, Jazz Pharmaceuticals and Kite Pharma.

Company Details

{}
Key Metrics
Founded Year
2020
Location
Mont-Saint-Guibert, Belgium
Stage
Acquired
Total Funding
$2.15M in 2 rounds
Latest Funding Round
Ranked
Employee Count
7 as on Sep 30, 2026
Similar Companies
Exit Details
Acquired by AstraZeneca (Mar 17, 2025)

EsoBiotec's acquisition details

EsoBiotec got acquired by AstraZeneca on Mar 17, 2025 at an acquisition amount of $*****.
Click here to take a look at EsoBiotec's acquisition in detail
Sign up to download EsoBiotec's company profile

EsoBiotec's funding and investors

EsoBiotec has raised a total funding of $2.15M over 2 rounds. Its first funding round was on 2021. Its latest funding round was a Series A round on Dec 11, 2023 for $*****. 1 investor participated in its latest round. EsoBiotec has 7 institutional investors.

Here is the list of recent funding rounds of EsoBiotec:
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Dec 11, 2023
9807664
Series A
1842886
6275224
8828831
6672215
2021
2376
Seed
4025
4166
4892
lockAccess funding benchmarks and valuations. Sign up today!

EsoBiotec's founders and board of directors

Founder? Claim Profile

EsoBiotec's employee count trend

EsoBiotec has 7 employees as of Sep 26. Here is EsoBiotec's employee count trend over the years:
Employee count trend for EsoBiotec
lockUncover EsoBiotec's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

EsoBiotec's Competitors and alternates

Top competitors of EsoBiotec include BeiGene, Jazz Pharmaceuticals and Kite Pharma. Here is the list of Top 10 competitors of EsoBiotec, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for BeiGene
BeiGene
2010, Cambridge (United States), Public
Developer of targeted and immune-oncology drugs against cancer
$172M
81/100
2nd
Logo for Jazz Pharmaceuticals
Jazz Pharmaceuticals
2003, Dublin (Ireland), Public
Developer of novel biopharmaceutical medicines for unmet medical needs
$265M
81/100
3rd
Logo for Kite Pharma
Kite Pharma
2009, Los Angeles (United States), Acquired
Developer of cancer immunotherapy products using genetic engineering
$97.7M
76/100
4th
Logo for Attovia
Attovia
2023, Fremont (United States), Public
Developer of antibody-based therapeutics for immune-mediated diseases and oncology
$255M
72/100
5th
Logo for Tango Therapeutics
Tango Therapeutics
2017, Cambridge (United States), Public
Developer of drugs for the treatment of cancer
$165M
72/100
6th
Logo for Syndax
Syndax
2005, Waltham (United States), Public
Developer of targeted therapies for the treatment of cancer
$198M
72/100
7th
Logo for Elicio
Elicio
2012, Cambridge (United States), Public
Developer of vaccines for treating cancer
$47.4M
72/100
8th
Logo for Moderna
Moderna
2010, Cambridge (United States), Public
Developer of mRNA-based therapeutics for a wide range of diseases
$2.78B
72/100
9th
Logo for Immuneel
Immuneel
2018, Bengaluru (India), Series B
Developer of T-cell therapies for the treatment of cancer
$49.8M
71/100
10th
Logo for BioNTech
BioNTech
2008, Mainz (Germany), Public
Developer of immunotherapeutics for the treatment of cancer and other diseases
$861M
71/100
535th
Logo for EsoBiotec
EsoBiotec
2020, Mont-Saint-Guibert (Belgium), Acquired
Developer of in vivo adoptive cell therapies for cancer and autoimmune diseases. This involves engineering immune cells directly within the patient's body, eliminating the need for complex ex vivo manufacturing and reducing the risks associated with traditional cell therapies. The company utilizes a proprietary vector platform to enable single-injection, off-the-shelf treatments, simplifying treatment logistics and reducing costs. The therapies are designed to minimize immune rejection and graft-versus-host disease, improving patient accessibility and quality of life. The platform is scalable, ensuring high-yield and high-purity production.
$2.15M
52/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on EsoBiotec's competitors? Click here to see the top ones

EsoBiotec's Investments and acquisitions

EsoBiotec has made no investments or acquisitions yet.

Reports related to EsoBiotec

Here is the latest report on EsoBiotec's sector:

News related to EsoBiotec

lockFilter this list
Media has covered EsoBiotec for 1 event in last 1 year.
•
•
AstraZeneca to acquire EsoBiotec for up to $1BBreaking The News•Mar 17, 2025•AstraZeneca, EsoBiotec
•
•
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about EsoBiotec

Explore our recently published companies
  • CoBooCo - Harrow based, 2010 founded, Unfunded company
  • BarBlackBook - 2009 founded, Unfunded company
  • Clyronex - South Africa based, 2016 founded, Unfunded company
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford